secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001193125-24-037559
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma prices $175.3M public offering of shares and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 4,488,159 ordinary shares at $19.00/share and 4,736,841 pre-funded warrants at $18.9999 each.
- Gross proceeds of approximately $175.3 million before underwriting discounts and expenses.
- Underwriters granted 30-day option for up to 1,383,750 additional shares, exercised in full.
- Net proceeds expected to be approximately $188.8 million including option exercise.
- Offering closed on February 16, 2024; Jefferies, Leerink, Piper Sandler, RBC Capital Markets as joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/0001193125-24-037559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/d790577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-037559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer